5,206
Views
34
CrossRef citations to date
0
Altmetric
Research Article

Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

, &
Pages 453-464 | Received 25 Apr 2016, Accepted 27 May 2016, Published online: 12 Jul 2016

References

  • Birrell MA, McCluskie K, Hardaker E, et al. (2006). Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model. Eur Respir J 28:1236–44.
  • Burstyn I. (2014). Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health 14:18.
  • Cahn Z, Siegel M. (2011). Electronic cigarettes as a harm reduction strategy for tobacco control: a step forward or a repeat of past mistakes. J Public Health Policy 32:16–31.
  • Caponnetto P, Auditore R, Russo C, et al. (2013). Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health 10:446–61.
  • Carmella SG, Chen M, Han S, et al. (2009). Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol 22:734–41.
  • Chambers DC, Tunnicliffe WS, Ayres JG. (1998). Acute inhalation of cigarette smoke increases lower respiratory tract nitric oxide concentrations. Thorax 53:677–9.
  • Deveci SE, Deveci F, Açik Y, Ozan AT. (2004). The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir Med 98:551–6.
  • D’Ruiz CD, Graff DW, Yan XS. (2015). Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. BMC Public Health 15:991.
  • Fagerström K. (2012). Determinants of tobacco use and renaming the FTND to the Fagerstrom test for cigarette dependence. Nicotine Tob Res 14:75–8.
  • Farsalinos KE, Polosa R. (2014). Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 5:67–86.
  • Farsalinos KE, Romagna G, Tsiapras D, et al. (2014). Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int J Environ Res Public Health 11:4356–73.
  • Farsalinos KE, Spyrou A, Tsimopoulou K, et al. (2014). Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep 4:4133.
  • Goniewicz ML, Knysak J, Gawron M, et al. (2014). Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 23:133–9.
  • Grana R, Benowitz N, Glantz SA. (2014). E-cigarettes: a scientific review. Circulation 129:1972–86.
  • Gregg EO, Minet E, McEwan M. (2013). Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 18:467–86.
  • Hajek P, Etter J-F, Benowitz N, et al. (2014). Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction 109:1801–10.
  • Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. (1991). The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 86:1119–27.
  • Hecht SS, Carmella SG, Kotandeniya D, et al. (2015). Evaluation of toxicant and carcinogen metabolites in the urine of E-cigarette users versus cigarette smokers. Nicotine Tob Res 17:704–9.
  • Hecht SS, Yuan J-M, Hatsukami D. (2010). Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol 23:1001–8.
  • Hecht SS, Carmella SG, Chen M, et al. (1999). Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 59:590–6.
  • Hecht SS, Murphy SE, Carmella SG, et al. (2004). Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 96:107–15.
  • Hecht SS. (2002). Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23:907–22.
  • Hogman M, Holmkvist T, Walinder R, et al. (2002). Increased nitric oxide elimination from the airways after smoking cessation. Clin Sci (Lond) 103:15–19.
  • Jarvis JM, Rusell MAH, Saloojee Y. (1980). Expired air carbon monoxide: a simple breath test of tobacco smoke intake. BMJ 281:484–5.
  • Kharitonov SA, Robbins RA, Yates D, et al. (1995). Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 152:609–12.
  • Malinovschi A, Janson C, Holmkvist T, et al. (2006). Effect of smoking on exhaled nitric oxide and flow-independent nitric oxide exchange parameters. Eur Respir J 28:339–45.
  • Mattes W, Yang X, Orr MS, et al. (2014). Biomarkers of tobacco smoke exposure. Adv Clin Chem 67:1–45.
  • McRobbie H, Phillips A, Goniewicz ML, et al. (2015). Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. Cancer Prev Res (Phila) 8:873–8.
  • McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. (2014). Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 12:CD010216.
  • Misra M, Leverette RD, Cooper BT, et al. (2014). E Comparative in vitro toxicity profile of electronic and tobacco cigarettes, smokeless tobacco and nicotine replacement therapy products: e-liquids, extracts and collected aerosols. Int J Environ Res Public Health 11:11325–47.
  • Pepper JK, Brewer NT. (2014). Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: a systematic review. Tob Control 23:375–84.
  • Polosa R, Rodu B, Caponnetto P, et al. (2013). A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J 10:19. doi:10.1186/1477-7517-10-19.
  • Polosa R, Caponnetto P, Morjaria JB, et al. (2011). Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health 11:786.
  • Ripoll J, Girauta H, Ramos M, et al. (2012). Clinical trial on the efficacy of exhaled carbon monoxide measurement in smoking cessation in primary health care. BMC Public Health 12:322.
  • Robbins RA, Millatmal T, Lassi K, et al. (1997). Smoking cessation is associated with an increase in exhaled nitric oxide. Chest 112:313–18.
  • Round EK, Campbell LR, Stiles MF, et al. (2015). Changes in biomarkers of exposure and subjective effects when smokers switch to dual use of cigarettes and either snus or a dissolvable tobacco product: a summary of three clinical studies. Beitr Tabakforsch Int 26:242–60.
  • Sarkar M, Liu J, Koval T, et al. (2010). Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus. Nicotine Tob Res 12:105–16.
  • Shahab L, Goniewicz M, Alwis U, et al. (2015). Exposure to selected toxicants and carcinogens as a function of smoking status and long-term use of nicotine replacement therapy or electronic cigarettes. Abstract presented at the 21st annual meeting of the Society for Research on Nicotine and Tobacco, Philadelphia, PA.
  • Taylor DR, Pijnenburg MW, Smith AD. (2006). Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 61:817–27.
  • Tayyarah R, Long GA. (2014). Comparison of select analytes in aerosol from e-cigarettes with smoke from conventional cigarettes and with ambient air. Reg Toxicol Pharmacol 70:704–10.
  • USFDA (2012). U.S. Food and Drug Administration, Center for Tobacco Products (CTP), Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List, April 2012. Available from: http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm [last accessed 17 Apr 2015].
  • USDHHS (2014). US Department of Health and Human Services. The Health Consequences of Smoking–50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
  • Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. (2010). A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidem Biomar 19:1945–53.
  • Walele T, Sharma G, Savioz R, et al. (2016). A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: safety and subjective effects. Reg Toxicol Pharmacol 74:187–92.
  • West R, Hajek P, Stead L, Stapleton J. (2005). Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 100:299–303.
  • Yan XS, D’Ruiz CD. (2015). Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul Toxicol Pharmacol 71:24–34.
  • Yates DH, Breen H, Thomas PS. (2001). Passive smoke inhalation decreases exhaled nitric oxide in normal subjects. Am J Respir Crit Care Med 164:1043–6.
  • Zhou M, Liu Y, Duan Y. (2012). Breath biomarkers in diagnosis of pulmonary diseases. Clin Chim Acta 413:1770–80.